We are live on ! Find out more
OPPM

Opus Point Partners Management Portfolio holdings

AUM $55.3M
1-Year Est. Return 7.48%
This Fund
S&P 500
This Quarter Est. Return
+20.38%
1 Year Est. Return
-7.48%
3 Year Est. Return
+85.18%
5 Year Est. Return
+168.21%
10 Year Est. Return
–
AUM
$101M
AUM Growth
–
Cap. Flow
+$93.1M
Cap. Flow %
92.16%
Top 10 Hldgs %
37.84%
Holding
57
New
57
Increased
–
Reduced
–
Closed
–
Avg Time Held Equity + Options
0 quarters
Top 10 Avg Time Held Equity + Options
0 quarters
Top 20 Avg Time Held Equity + Options
0 quarters
Avg Time Held Equity only
0 quarters
Top 10 Avg Time Held Equity only
0 quarters
Top 20 Avg Time Held Equity only
0 quarters

Top Buys

Rank Stock Value
1
BIB icon
ProShares Ultra NASDAQ Biotechnology
BIB
+$4.48M
2
INCY icon
Incyte
INCY
+$3.98M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$3.64M
4
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$3.56M
5
CELG
Celgene Corp
CELG
+$3.48M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 70.4%
2 Miscellaneous 29.6%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
BIB icon
1
ProShares Ultra NASDAQ Biotechnology
BIB
$93.2M
$4.79M 4.74%
+76,368
New +$4.48M
2014 Q4
0 quarters
INCY icon
2
Incyte
INCY
$22.9B
$4.45M 4.4%
+60,877
New +$3.98M
2014 Q4
0 quarters
BMRN icon
3
BioMarin Pharmaceuticals
BMRN
$10.6B
$3.95M 3.91%
+43,731
New +$3.64M
2014 Q4
0 quarters
XBI icon
4
State Street SPDR S&P Biotech ETF
XBI
$10.2B
$3.88M 3.84%
+62,400
New +$3.56M
2014 Q4
0 quarters
CELG
5
DELISTED
Celgene Corp
CELG
$3.7M 3.66%
+33,040
New +$3.48M
2014 Q4
0 quarters
NKTR icon
6
Nektar Therapeutics
NKTR
$1.41B
$3.68M 3.64%
+15,807
New +$3.38M
2014 Q4
0 quarters
REGN icon
7
Regeneron Pharmaceuticals
REGN
$76.9B
$3.55M 3.51%
+8,650
New +$3.4M
2014 Q4
0 quarters
VRTX icon
8
Vertex Pharmaceuticals
VRTX
$129B
$3.46M 3.42%
+29,096
New +$3.28M
2014 Q4
0 quarters
ILMN icon
9
Illumina
ILMN
$42B
$3.4M 3.36%
+18,909
New +$3.33M
2014 Q4
0 quarters
ALXN
10
DELISTED
Alexion Pharmaceuticals
ALXN
$3.39M 3.36%
+18,332
New +$3.4M
2014 Q4
0 quarters
CPHD
11
DELISTED
Cepheid Inc
CPHD
$3.27M 3.23%
+60,386
New +$3.05M
2014 Q4
0 quarters
BIIB icon
12
Biogen
BIIB
$33.3B
$3.22M 3.19%
+9,486
New +$3.07M
2014 Q4
0 quarters
PCYC
13
DELISTED
PHARMACYCLICS INC
PCYC
$3.15M 3.11%
+25,723
New +$3.29M
2014 Q4
0 quarters
MDVN
14
DELISTED
MEDIVATION, INC.
MDVN
$3.13M 3.09%
+62,754
New +$3.26M
2014 Q4
0 quarters
MTD icon
15
Mettler-Toledo International
MTD
$31.1B
$3.02M 2.99%
+10,000
New +$2.75M
2014 Q4
0 quarters
RCPT
16
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
$2.81M 2.78%
+22,971
New +$2.33M
2014 Q4
0 quarters
IONS icon
17
Ionis Pharmaceuticals
IONS
$7.52B
$2.8M 2.77%
+45,418
New +$2.24M
2014 Q4
0 quarters
AMGN icon
18
Amgen
AMGN
$224B
$2.71M 2.69%
+17,046
New +$2.66M
2014 Q4
0 quarters
QGENF
19
DELISTED
QIAGEN NV
QGENF
$2.67M 2.65%
+114,000
New +$2.67M
2014 Q4
0 quarters
SGEN
20
DELISTED
Seagen Inc. Common Stock
SGEN
$2.64M 2.61%
+82,253
New +$2.87M
2014 Q4
0 quarters
TECH icon
21
Bio-Techne
TECH
$11.4B
$2.58M 2.55%
+111,600
New +$2.55M
2014 Q4
0 quarters
UTHR icon
22
United Therapeutics
UTHR
$23.6B
$2.47M 2.44%
+19,054
New +$2.46M
2014 Q4
0 quarters
SLXP
23
DELISTED
SALIX PHARMACEUTICALS LTD DEL
SLXP
$2.09M 2.07%
+18,187
New +$2.2M
2014 Q4
0 quarters
GEVA
24
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
$1.86M 1.84%
+20,002
New +$1.58M
2014 Q4
0 quarters
ALNY icon
25
Alnylam Pharmaceuticals
ALNY
$31.1B
$1.73M 1.72%
+17,875
New +$1.66M
2014 Q4
0 quarters
1
2 3

Similar funds

KIA
Kopp Investment Advisors Bloomington, Minnesota $54.4M AUM 14.33% 1-Year Est. Return
PGA
Premia Global Advisors Coral Gables, Florida $57.9M AUM 2.91% 1-Year Est. Return
GX
Greylock XII Menlo Park, California $51.9M AUM 11.52% 1-Year Est. Return
SCG
Saban Capital Group Los Angeles, California $59.5M AUM 3.83% 1-Year Est. Return
TCMV
Technology Crossover Management VI Menlo Park, California $59.6M AUM 18.81% 1-Year Est. Return
FCM
Farmstead Capital Management Ridgewood, New Jersey $49M AUM 10.57% 1-Year Est. Return
DP
DW Partners New York $62.3M AUM 25.52% 1-Year Est. Return
SAM
Sheffield Asset Management Chicago, Illinois $48.1M AUM 12.96% 1-Year Est. Return

Opus Point Partners Management's Q4 2014 Portfolio in Review

Q4 2014 is the first quarter with a 13F filing on record for Opus Point Partners Management, which disclosed 57 positions worth $101M. Its ten largest holdings account for 38% of the portfolio.

Its largest position is ProShares Ultra NASDAQ Biotechnology: 76,368 shares worth $4.79M.

By sector, the portfolio is most concentrated in Healthcare at 70% of assets, followed by Miscellaneous.

  • Opus Point Partners Management's largest Q4 2014 buy was ProShares Ultra NASDAQ Biotechnology: 76,368 shares worth $4.79M.
  • Opus Point Partners Management's ten largest holdings make up 38% of its $101M portfolio in Q4 2014.
  • Opus Point Partners Management disclosed 57 positions in Q4 2014, its first 13F filing on record.

Based on Opus Point Partners Management's 13F filing for Q4 2014, filed 17 Feb 2015.